Patents by Inventor Naoji Umemoto

Naoji Umemoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5030719
    Abstract: Cytotoxic antibody conjugates in which a folic acid-antagonistic folic acid analogue is bound to an antibody or its fragment through an oligopeptide. The conjugates can be used as a chemotherapeutic agent against malignant tumors.
    Type: Grant
    Filed: April 27, 1988
    Date of Patent: July 9, 1991
    Assignee: Teijin Limited
    Inventors: Naoji Umemoto, Yoshinori Kato, Takeshi Hara
  • Patent number: 4543211
    Abstract: A conjugate having cytotoxicity prepared by covalently binding a polymer which has cytotoxic substances linked to its side chains and a reactive group at its terminal to an immunoglobulin, or its fragment, which is capable of selectively binding to a particular antigen possessed by cells to be killed.
    Type: Grant
    Filed: December 21, 1983
    Date of Patent: September 24, 1985
    Assignee: Teijin Limited
    Inventors: Yoshinori Kato, Naoji Umemoto, Takeshi Hara, Yutaka Tsukada, Hidematsu Hirai
  • Patent number: 4507234
    Abstract: A conjugate having cytotoxicity prepared by covalently binding a serum albumin having cytotoxic substance linked thereto to an immunoglobulin, or its fragment, which is able to bind selectively with a particular antigen of cells to be killed.
    Type: Grant
    Filed: December 21, 1983
    Date of Patent: March 26, 1985
    Assignee: Teijin Limited
    Inventors: Yoshinori Kato, Naoji Umemoto, Masahiko Saito, Takeshi Hara
  • Patent number: 4487714
    Abstract: A cytocidal modified immunoglobulin expressed by formula (I) ##STR1## (wherein Ab represents an immunoglobulin or its fragment; R represents a divalent organic group; and n is an integer from 1 to 20).
    Type: Grant
    Filed: January 18, 1984
    Date of Patent: December 11, 1984
    Assignee: Teijin Limited
    Inventors: Yoshinori Kato, Naoji Umemoto, Yumiko Takeda, Takeshi Hara
  • Patent number: 4379145
    Abstract: Antitumor protein hybrid, having a moiety consisting of the antitumor immunoglobulin and a moiety substantially consisting of the fragment A of a diphtheria toxin, which is expressed by the following formula (I):Ab(NHCO--X--S.sub.1 --S.sub.2 --FA).sub.n (I)(where Ab indicates a moiety consisting of the antitumor immunoglobulin and FA indicates a moiety substantially consisting of the fragment A of a diphtheria toxin; X is an alkylene group or phenylene group which either has or does not have a branching of 1 to 5 carbon atoms. N in the amido bond is a nitrogen atom arising from the amino group in the antitumor immunoglobulin; S.sub.1 and S.sub.2 are both sulfur atoms, S.sub.2 indicating a sulfur atom arising from the disulfide bond in a diphtheria toxin; n stands for an integer of 1 to 5).This antitumor protein hybrid has remarkable and specific citotoxicity against tumor cells.
    Type: Grant
    Filed: December 15, 1980
    Date of Patent: April 5, 1983
    Assignees: Teijin Limited, Hidematsu Hirai
    Inventors: Yasuhiko Masuho, Naoji Umemoto, Takeshi Hara, Hidematsu Hirai
  • Patent number: 4357273
    Abstract: Antitumor protein hybrid, composed of a moiety which is substantially the fragment Fab of an anti-.alpha.-fetoprotein antibody and a moiety which is substantially the fragment A of a diphtheria toxin, which is expressed by the following formula (I):Fab--(S.sub.1 --(X).sub.n --S.sub.2 --FA).sub.m (I)(where Fab indicates a moiety which is substantially the fragment Fab of an anti-.alpha.-fetoprotein antibody; FA indicates a moiety which is substantially the fragment A of diphtheria toxin; X indicates a divalent organic radical; S.sub.1 and S.sub.2 are both sulfur atoms, S.sub.1 indicating a sulfur atom arising from the disulfide bond (--S--S--bond) in an anti-.alpha.-fetoprotein antibody and S.sub.2 a sulfur atom arising from the disulfide bond in a diphtheria toxin; n stands for 0 or 1 and m stands for an integer of 1 to 5). This antitumor protein hybrid has remarkable and specific citotoxicity against tumor cells.
    Type: Grant
    Filed: July 21, 1980
    Date of Patent: November 2, 1982
    Assignees: Teijin Limited, Hidematsu Hirai
    Inventors: Yasuhiko Masuho, Naoji Umemoto, Takeshi Hara, Hidematsu Hirai